SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hansen Jesper)
 

Search: WFRF:(Hansen Jesper) > Treatment-free remi...

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

Flygt, Hjalmar (author)
Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
Söderlund, Stina (author)
Uppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
Richter, Johan (author)
Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden
show more...
Saussele, Susanne (author)
Medical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany,Heidelberg Univ, Germany
Koskenvesa, Perttu (author)
Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland
Stenke, Leif (author)
Karolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden
Mustjoki, Satu (author)
Department of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland; ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland; Univ Helsinki, Finland; Univ Helsinki, Finland; ICAN Digital Precis Canc Med Flagship, Finland
Dimitrijevic, Andreja (author)
Department of Hematology, Odense University Hospital, Odense, Denmark,Odense Univ Hosp, Denmark
Stentoft, Jesper (author)
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark,Aarhus Univ Hosp, Denmark
Majeed, Waleed (author)
Department of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway,Stavanger Univ Hosp, Norway
Roy, Lydia (author)
French CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France,Univ Paris Est Creteil, France; Univ Paris Est Creteil, France
Wolf, Dominik (author)
Department of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria; Medical Clinic 3, Universitätsklinikum, Bonn, Germany,Med Univ Innsbruck, Austria; Univ Klinikum Bonn, Germany
Dreimane, Arta (author)
Department of Hematology, Linköping University Hospital, Linköping, Sweden,Region Östergötland, Hematologiska kliniken US
Gjertsen, Bjørn Tore (author)
Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway,Haukeland Hosp, Norway
Gedde-Dahl, Tobias (author)
Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,Natl Hosp Norway, Norway
Ahlstrand, Erik, 1974- (author)
Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Medicine,Orebro Univ, Sweden
Markevärn, Berit (author)
Department of Hematology, Umeå University Hospital, Umeå, Sweden,Umea Univ Hosp, Sweden
Hjorth-Hansen, Henrik (author)
Department of Hematology, St. Olavs Hospital, Trondheim, Norway,St Olavs Hosp, Norway
Janssen, Jeroen (author)
Department of Hematology, Radboud University medical center, Nijmegen, The Netherlands,Radboud Univ Nijmegen, Netherlands
Olsson-Strömberg, Ulla (author)
Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden
show less...
 (creator_code:org_t)
2024
2024
English.
In: Leukemia. - : Springer. - 0887-6924 .- 1476-5551.
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2nd stop. After a median follow-up of 27 months from 2nd stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2nd TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Keyword

Medicinsk vetenskap
Medical Science

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view